Humalog Tempo Pen (Insulin Lispro)

Humalog Tempo Pen is indicated for the management of blood glucose in adults and children with diabetes.

• Type 1 diabetes mellitus requiring mealtime insulin.
• Type 2 diabetes mellitus when rapid‑acting insulin is needed.
• Prandial (mealtime) glucose control to cover carbohydrate intake.
• Flexible dose adjustment based on meals and activity.
• Transition from multiple daily injections to a prefilled pen system.

• Insulin lispro is a rapid‑acting insulin analog that binds to the insulin receptor on muscle, adipose and hepatic cells. Binding activates the receptor’s intrinsic tyrosine kinase, promoting translocation of GLUT‑4 transporters to the cell surface and enhancing glucose uptake. It also suppresses hepatic gluconeogenesis, leading to a quick reduction in plasma glucose levels after meals. The analog’s altered amino‑acid sequence reduces self‑association, allowing faster absorption from the subcutaneous tissue.

Adverse reactions to Humalog Tempo Pen are generally consistent with other rapid‑acting insulins and can be grouped by frequency.

Common

• Hypoglycemia (low blood glucose).
• Redness, swelling, or pain at the injection site.
• Lipodystrophy or lipoatrophy at injection sites.
• Transient weight gain.
• Headache.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic reactions such as rash, urticaria, or angioedema.
• Anaphylaxis.
• Hypokalemia.
• Insulin‑induced edema.

When using Humalog Tempo Pen, several safety considerations should be observed.

• Monitor blood glucose regularly to avoid hypoglycemia.
• Rotate injection sites to reduce lipodystrophy.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be altered.
• Pregnancy and lactation status should be evaluated; the safety profile is not fully established.
• Educate patients on recognizing signs of severe hypoglycemia.
• Store the pen according to manufacturer instructions to maintain potency.

Humalog Tempo Pen can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Other rapid‑acting insulins or concentrated insulin formulations that may cause stacking.
• Beta‑blockers, which can mask hypoglycemia symptoms.
• MAO inhibitors that may potentiate insulin’s effect.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which raise blood glucose levels.
• Thiazide diuretics, which may affect potassium balance.
• Alcohol, which can cause delayed hypoglycemia.